Phase Ultra Performance Liquid Chromatography Research Articles

A rapid and novel quantitative determination of Lecanemab monoclonal antibody for Alzheimer’s disease using reverse phase ultra performance liquid chromatography

A novel humanized IgG1 monoclonal antibody known as Lecanemab is used to treat Alzheimer’s disease. Utilizing the RP-UPLC technique, the current investigation aims to develop a robust, stable and rapid method for determining Lecanemab. By applying this method, the ultimate chromatographic conditions were obtained using a BEH C8 (1.7 μm, 2.1 x 100 mm) and a mobile phase prepared with acetonitrile and formic acid buffer in a 7: 3 ratio, respectively (1.0 mL of formic acid diluted in 1 liter of HPLC-grade water), by means of adopting isocratic elution. Detection limit (LOD) and quantitation limit (LOQ) were 0.30 and 1.00 μg/mL, respectively, and linearity (R2 = 0.999) was demonstrated in the range of 25-150 μg/mL of working concentration with PDA detection at 219 nm. The results of the forced degradation investigation also make it evidently visible; the drug’s degradation products could be separated from the main peak, assuring the effectiveness of the stability-indicating method. Thus, routine analysis and stability studies favor of enormously from the use of this method of analysis.

Isolation, characterization, identification and quantification of 6-F oxyphenisatin dipropionate, a novel illegal additive, from a fruit-flavored jelly

ObjectiveThis study is aimed to screen, identify and detect illegal additives from healthcare products which claim or imply to have weight-loss effects. MethodUltra-high performance liquid chromatography-quadruple-time-of-flight mass spectroscopy (UPLC-Q-TOF/MS) was employed to perform non-targeted screening of illegal additives from a total of 26 batches of healthcare products with weight-loss effects. A novel oxyphenisatin dipropionate analog was discovered in a fruit-flavored jelly that was not clearly labeled as containing added drugs. After being separated and purified by silica gel column chromatography, the analog was unambiguously characterized by one-dimensional (1D) and two-dimensional (2D) nuclear magnetic resonance (NMR) spectroscopies. The molecular structure of the analog was finally identified by comparing the spectra of the analog with those of suspected candidates prepared by de novo synthesis strategy. Thereafter, a sensitive and precise reversed phase ultra performance liquid chromatography coupled with photodiode array (UPLC-PDA) detection method was developed and verified for the determination of the analog in 15 batches of real samples. ResultsIn the MS/MS spectra, the signal intensity of mass/charge ratios (m/z, 242 and 214) of the novel analog fragments was highly similar to that of mass/charge ratios (m/z, 224 and 196) of oxyphenisatin dipropionate fragments. Additionally, the 1D NMR spectrum of the analog was completely consistent with that of one of the suspected candidates prepared by the de novo synthesis strategy. Based on the above analysis, the structure of the analog was determined as 3,3-bis[4'-(propionyloxy)phenyl]-6-fluoro-2-oxoindoline, which was briefly named 6-F oxyphenisatin dipropionate. A developed quantitative method showed good linearity (R2 > 0.999) in a concentration range of 1.0–100 μg/mL. The limits of detection (LOD) and quantification (LOQ) for the analog was 3 mg/kg and 10 mg/kg, respectively. The average recoveries of the analog from spiked three different matrix samples in low (1 time of LOQ), medium (2 times of LOQ), and high (10 times of LOQ) concentrations were varied from 93.9 % to 107.8 % with a precision of 0.03–1.56 %. Results of quantitative analysis in 15 batches of healthcare products revealed that the content of 6-F oxyphenisatin dipropionate in a fruit-flavored jelly and a solid beverage was 118 mg/kg and 330 mg/kg, respectively. ConclusionIn terms of its structure, 6-F oxyphenisatin dipropionate replaces hydrogen atom by the fluorine atom at position 6 on the indolinone fragment in oxyphenisatin dipropionate. To our best knowledge, 6-F oxyphenisatin dipropionate has never been detected as an illegal additive in foods. Such illegal addition of the analog to foods is more concealing, thus the supervision and testing departments should attach great importance to its application in food markets.

Development and validation of a stability-indicating analytical method for simultaneous determination of sodium phenylbutyrate and taurursodiol in bulk and formulation using reverse phase ultra-performance liquid chromatography

Background Amyotrophic Lateral Sclerosis, often known as Lou Gehrig’s disease, is typically treated with a combination therapy that includes both sodium phenylbutyrate (SPB) and taurursodiol (TRS). Objectives To assess both SPB and TRS in bulk and their dosage form concurrently, a stability-indicating analytical method was developed and validated using Ultra-Performance Liquid Chromatography. Patients and methods The chromatographic separation was carried out on a Waters C18 Column, with dimensions of 150×4.6 mm i.d. and a particle size of 2 μm. A mobile phase consisting of a phosphate buffer pH 2.5 with methanol in the ratio of 45 : 65 v/v was, then delivered at a flow rate of 1 ml/min. Detection of the analytes occurred at 285 nm using a photo diode array detector. An auto sampler injected a 10 μl sample into the column, and the column was maintained at a temperature of 30°C. Results and conclusion SPB and TRS were eluted at 1.483 and 2.492 nm, respectively. Linearity was established in the range of 567–1701 μg/ml for SPB and 189–567 μg/ml for TRS. The robustness of the method was assessed by intentionally modifying parameters such as flow rate, detection wavelength, and column temperature. Furthermore, studies on forced degradation under various stress conditions, including acid, base, peroxide, heat, and ultra violet exposure, indicated the method’s capability to identify stable materials. In summary, the developed analytical approach for simultaneously determining SPB and TRS in bulk and their formulation was found to be specific, accurate, precise, and reliable.

The development and validation of a stability indicating Rp-UPLC method for the simultaneous estimation of clarithromycin, amoxicillin, and vonoprazan in a physical mixture

A novel technique was developed for simultaneous quantification of clarithromycin (CLA) amoxicillin (AMO), and vonoprazan (VON) in a mixture using the reverse phase ultra-performance liquid chromatography (RP-UPLC) technique and validated as per International Council for Harmonization (ICH) guidelines as there was no literature published for its estimation by UPLC. The method was developed using an acquity UPLC system from waters corporation with Hibar Bis phosphonate C18 column (100 × 2.1 mm, 2 μm) at 35°C and tunable ultra-violet detector (TUV) with detection wavelength at 210 nm, has a run time of below 3 minutes. The mobile phase proportion of 60:40 of 0.1 N monobasic potassium phosphate buffer (pH 3.8) and acetonitrile at a flow velocity of 0.2 ml/ minute was utilized. Linearity was observed for CLA, AMO, and VON between the concentration ranges of 25–150, 25–150, and 1–6 μg/ml, respectively, and R2 was 0.999 for CLA, AMO, and VON. Accuracy and precision were within 2% of the coefficient of variation (RSD) for all drugs. The observed mean percentage recoveries for the CLA, AMO, and VON were determined to be 99.74%, 99.07%, and 99.8%, respectively. The stability of the approach was assessed using degradation studies by exposing it to acid, alkali, oxidizing agent, heat, Ultra Violet (UV) light, and water as per ICH guidelines.

Characterisation of the forest cobra (Naja melanoleuca) venom using a multifaceted mass spectrometric-based approach

Snake venoms consist of highly biologically active proteins and peptides that are responsible for the lethal physiological effects of snakebite envenomation. In order to guide the development of targeted antivenom strategies, comprehensive understanding of venom compositions and in-depth characterisation of various proteoforms, often not captured by traditional bottom-up proteomic workflows, is necessary. Here, we employ an integrated ‘omics’ and intact mass spectrometry (MS)-based approach to profile the heterogeneity within the venom of the forest cobra (Naja melanoleuca), adopting different analytical strategies to accommodate for the dynamic molecular mass range of venom proteins present. The venom proteome of N. melanoleuca was catalogued using a venom gland transcriptome-guided bottom-up proteomics approach, revealing a venom consisting of six toxin superfamilies. The subtle diversity present in the venom components was further explored using reversed phase-ultra performance liquid chromatography (RP-UPLC) coupled to intact MS. This approach showed a significant increase in the number of venom proteoforms within various toxin families that were not captured in previous studies. Furthermore, we probed at the higher-order structures of the larger venom proteins using a combination of native MS and mass photometry and revealed significant structural heterogeneity along with extensive post-translational modifications in the form of glycosylation in these larger toxins. Here, we show the diverse structural heterogeneity of snake venom proteins in the venom of N. melanoleuca using an integrated workflow that incorporates analytical strategies that profile snake venom at the proteoform level, complementing traditional venom characterisation approaches.

Stability Indicating Reverse Phase Ultra Performance Liquid Chromatography Method Development and Validation for Amiloride and Hydrochlorothiazide Tablet in the Presence of Degradation Products and Application to Green Analytical Principles

Amiloride (AML) and hydrochlorothiazide (HCTZ) combination is used alone or with other medicines to treat high blood pressure (hypertension). The present article provides the development and validation of an reverse phase ultra performance liquid chromatography (RP-UPLC) approach for the quantification of AML, HCTZ, and related impurities in pharmaceutical dosage forms. The analytical column used for the separation of impurities is the Waters X bridge C18 3.5 μm (50 mm X 4.6 mm). Used 0.1% formic acid and ethanol as MP in an isocratic mode with 0.3 mL/min as flow rate and 3 μL as injection volume, at 254 nm as detection in UV and 12 minutes as total run time. The samples were prepared specifically to undergo forced degradation, which involved subjecting them to hydrolysis, oxidation, thermal, and photolytic conditions. The technique underwent validation by the principles set forth by the ICH Q2 guidelines. The validation confirmed that the method possesses specificity, linearity, ruggedness, robustness and accuracy. The methodology employed exhibited a linear relationship extending from 10 to 150% for all impurities. The recovery analysis was conducted throughout a range of concentrations, starting from 10 to 150% concentration. The average recovery value was determined to be within acceptable limits. The evidence of degradation and the findings of the verified study suggest that the nature of the subject under investigation is stable. Hence, this approach might be employed within the domains of pharmaceutical research and development and quality control departments. Green analytical chemistry tools are used to assess the method’s greenness and calculated using GAPI, AGREE and ecological-scale and found excellent green of >75%.

Simultaneous UPLC Assay for Oxitropium Bromide and Formoterol Fumarate Dihydrate in Pressurized Metered Dose Inhaler Products for Chronic Obstructive Pulmonary Disease.

Oxitropium bromide (OB) and formoterol fumarate dihydrate (FFD) are inhaler molecules that are widely used in the treatment of chronic lung diseases. The goal of this work was to create a reversed phase-ultra performance liquid chromatography (RP-UPLC) technique for assay and identification of OB and FFD, as well as identification and estimate of its associated compounds in pressurized metered dose inhaler product (pMDI). Separation of oxitropium and formoterol peaks were enhanced on a C18 (50 × 2.1 mm × 1.7 μm) UPLC column with ethylene-bridged-hybrid technology, The mobile phase consists of buffer (0.07 M KH2PO4) and acetonitrile (80:20, v/v). The detector wavelength of 210 nm, flow rate of pump 0.6 mL/min, and oven temperature for column were set at 25°C. The injection volume was 10 μL. The method run time was 2 min. The mobile phase was used as the solvent. Retention times (RTs) were 0.5 min for OB and 1.0 min for FFD. The assay analysis was linear range for all analytes within the range for concentrations 0.03-14.8 µg/mL of OB, 0.01-0.88 µg/mL of FFD. LOD values and LOQ values 0.009 and 0.026 µg/mL for OB and 0.003 and 0.009 µg/mL for FFD, respectively. Recoveries were obtained at 96.3% for OB and 97.2% for FFD. Precisions values were (as RSD, %) ≤1.5%. With the UPLC method developed and validated according to the current ICH guidelines, it is possible to simultaneously detect OB and FFD of assay analysis in pMDI products accurately, precisely and selectively, independent of the matrix effect. The present method is the first method in the literature based on the UPLC method for this purpose. The UPLC method is a time-saving method, it provides a faster and cheaper technique than the high performance liquid chromatography (HPLC) method.

Determination of Clorsulon and its related substances in commercial bulk drug substance batches by a rapid ion-pair UPLC method

Clorsulon is a potent anthelmintic agent and is widely used for the treatment and control of parasites including adult liver flukes in cattle and sheep. A rapid ion-paired reversed phase ultraperformance liquid chromatography (IP-UPLC) method has been developed and validated for determination of Clorsulon and its related substances in bulk drug substance batches of Clorsulon with a short octadecyl column. Analytes were eluted by a gradient elution on a Acquity UPLC® BEH C18 column (50 mm × 2.1 mm i.d., 1.7 µm particle size). Column temperature was maintained at 55 °C and all analytes were monitored by UV detection at 268 nm. Mobile phase-A constitutes 3 mM tetrabutylammonium hydroxide in H2O and mobile phase-B constitutes acetonitrile/methanol (50/50, v/v), respectively. All analytes of interest were adequately separated within 5 min. The analytes were quantitated against an external reference standard of Clorsulon. The chemical structures of degradation products of Clorsulon were proposed based on two-dimensional UPLC-MS data. The IP-UPLC method has been successfully validated and demonstrated to be accurate, sensitive, robust, and specific.

Development and Validation of a New Reverse Phase Ultra Performance Liquid Chromatography Method for the Estimation of Related Substances of the Anticancer Drug Zanubrutinib and Characterization of its Degradants Using Liquid Chromatography Mass Spectrometry

Development and Validation of a New Reverse Phase Ultra Performance Liquid Chromatography Method for the Estimation of Related Substances of the Anticancer Drug Zanubrutinib and Characterization of its Degradants Using Liquid Chromatography Mass Spectrometry

A Novel Stability Indicating Reversed Phase Ultra Performance Liquid Chromatography Method for Estimation of Asciminib its Bulk and Tablet Formulation

The key objective of the proposed study was to creat and validate an economical, perceptive, specific, reliable and simple reversed phase ultra-performance liquid chromatography (RP-UPLC) method with better response was anticipated for the investigation of asciminib bulk powder and its tablet form. UPLC system (WATERS, Model-2695) connected with PDA (Model-2996) detector was opted to made the present method. To separate asciminib proficiently, method conditions such as C18 column (50 x 4.6 mm, 1.7 m), mobile system of trifluoro aceticacid (TFA) in water (0.1%) and acetonitrile in 75:25 v/v, 0.3 mL/min flow rate and 260 nm wavelength were used as optimized chromatographic conditions. The anticipated method was validated by the ICH specifications. The retention time of asciminib was noticed at 0.925 minute with good efficiency, respectively. Linearity was noticed for concentrations ranging fom 5 to 30 μg/mL of asciminib with R2 value of 0.999. The %RSD of both system and method precision was assessed in the range of 0.49 to 0.86. The percentage recovery of asciminib was in the range of 100.06–100.6%. The logarithm of the odds (LoD) and limit of quantitation (LoQ) of asciminib determined to be 0.23 and 0.69 μg/mL correspondingly. The results confirmed that the projected technique was economical, simple, responsive and precise. Exploration of asciminib under various FD environments confirms the stability representing the nature of the stated method. The proposed UPLC method is extremely valuable in the separation and estimation of asciminib.

STABILITY INDICATING METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF PREGABALIN AND ETORICOXIB IN BULK AND TABLET DOSAGE FORM BY UPLC

A simple, accurate and precise reverse phase ultra-performance liquid chromatography method was developed and validated for simultaneous estimation of Pregabalin and Etoricoxib in formulations as well as in pure form. The developed method was shown acceptable separation of pregabalin and Etoricoxib. The retention times for Pregabalin and Etoricoxib were 1.134 min. & 1.535 min. respectively. The limits of detection and quantification were obtained from regression equations and observed to be 0.85ppm and 0.54ppm for Pregabalin, 2.58 and 1.62ppm for Etoricoxib, respectively. Degradation studies of the tablet dosage form under stress conditions of acid, base, oxidation , temperature, water, UV light indicated that the method was particular with no interferences from any of the potential impurities that could form over the shelf life. The new developed RP-UPLC method which was sensitive, accurate stability indicating and fast, for active pharmaceutical ingredients and dosage forms. Key words: Pregabalin, Etoricoxib, Simultaneous, Reverse Phase - UPLC

Development and validation of novel rapid stability indicating mass compatible UPLC method for the simultaneous estimation of assay and related substances of oxytocin bulk and assay of injectable dosage form

Developed and validated a simple, rapid, new mass compatible reverse phase ultra-performance liquid chromatography (UPLC) method for the simultaneous estimation of Assay and related substance of Oxytocin in bulk and extending the same method to injectable dosage form for the estimation of Assay. The developed method is capable of separating all the potential process and degradation impurities within 15 minutes. Chromatography was carried out using Waters Acquity CSH C18 column (50 mm length, 2.1 mm internal diameter and 1.7μ particle size) with gradient elution. 0.1% Trifluoroacetic acid used as Mobile phase A and mixture of 0.1% Trifluoroacetic acid and Acetonitrile in the ratio of 50:50 v/v was used as Mobile phase B. The flow rate of the mobile phase was set at 0.4 mL/min and the column temperature was maintained at 35°C. The detection was carried out using UV detector at 220 nm. The Retention time of Oxytocin is about 3 minutes and all the potential impurities are eluted within 10 minutes. Method validation was performed according to ICH (International Conference on Harmonization) guidelines. The validated method is simple, rapid, mass compatible, economical, specific, accurate, linear, precise, rugged, sensitive, robust and stability indicating.

A Study of Stability Indicating Development and Validation of a Method for Simultaneous Estimation of Brigatinib and Alectinib Using Reverse Phase Ultra Performance Liquid Chromatography in Active Pharmaceutical Ingredient Form

Aims: New validated method for the simultaneous estimation of Brigatinib and Alectinib using UPLC and study of its degradation.
 Place and Duration of Study: Department of Chemistry, RVR & JC College of Engineering, Chowdavaram, Guntur, Andhra Pradesh, between March 2021 and April 2021.
 Methodology: Using Luna C18 100 x 2.6 mm, 1.6 µm column, acetonitrile, and 0.1 percent Tri ethyl amine (TEA) (80:20 v/v) as a mobile phase, the proposed method successfully achieved effective chromatographic separation with a flow rate of 1 mL/min and a wave length of 260 nm. The Braginib and Alectinib peaks were resolved within 5 minutes of elution time, with the Brigatinib peak eluting at 3.208 minutes and the Alectinib peak eluting at 1.757 minutes.
 Results: The proposed method displays excellent linearity in the concentration ranges of 1.0 µg/ml to 15 µg/ml for Brigatinib and 5.0 µg/ml to 75 µg/ml for Alectinib. The RSD of robustness levels has a maximum of just 2 percent.
 Conclusion: The accuracy, specificity, and sensitivity of the method were all found to be in line with ICH guidelines, when the procedure was developed and tested.

Determination of Umbralisib using reverse phase ultra performance liquid chromatography in bulk and pharmaceutical dosage form

Determination of Umbralisib using reverse phase ultra performance liquid chromatography in bulk and pharmaceutical dosage form

Quantification of Lipid and Peptide Content in Antigenic Peptide-loaded Liposome Formulations by Reversed-phase UPLC using UV Absorbance and Evaporative Light Scattering Detection

Antigenic peptide-loaded cationic liposomes have shown promise as cancer vaccines. Quantification of both peptides and lipids is critical for quality control of such vaccines for clinical translation. In this work we describe a reversed phase ultra-performance liquid chromatography (RP-UPLC) method that separates lipids (DOTAP, DOPC and their degradation products) and two physicochemically different peptides within 12 min. Samples were prepared by dilution in a 1:1 (v/v) mixture of methanol and water. Peptide quantification was done via UV detection and lipids were quantified by an evaporative light scattering detector (ELSD), both coupled to the RP-UPLC system, with high precision (RSD < 3.5%). We showed that the presence of lipids and peptides did not mutually influence their quantification. Limit of detection (LOD) and limit of quantification (LOQ), as determined in the ICH guidelines, were 6 and 20 ng for DOTAP, 12 ng and 40 ng for DOPC, 3.0 ng and 8.0 ng for peptide A and 2.4 ng and 7.2 ng for the more hydrophobic peptide B. Finally, lipid degradation of DOTAP and DOPC was monitored in peptide loaded DOTAP:DOPC liposomes upon storage at 4 °C and 40 °C.

Development and Validation of Novel Rapid Stability Indicating Mass Compatible UPLC Method for the Simultaneous Estimation of Assay and Related Substances of Remdesivir in Bulk and Injectable Dosage Form

Developed and validated a simple, rapid, new mass compatible reverse phase ultra-performance liquid chromatography (UPLC) method for the simultaneous estimation of assay and related substance of remdesivir in bulk and injectable dosage form. The developed method is capable of separating all the potential process and degradation impurities within 15 min. Chromatography was carried out using Waters Acquity BEH C18 column (50 mm length, 2.1 mm internal diameter and 1.7 μ particle size) with gradient elution. Ghost buster column (30 mm length, 2.1 mm internal diameter) was used as inline filter to suppress the response of peaks originating from mobile phase. Mobile phase A composed of 10 mM ammonium acetate buffer pH 3.5 and acetonitrile in the ratio of 90:10 v/v and mobile phase B composed of 10 mM ammonium acetate buffer pH 3.5 and acetonitrile in the ratio of 10:90 v/v. The flow rate of the mobile phase was set at 0.35 mL/min and the column temperature was maintained at 35 ºC. The detection was carried out using UV detector at 245 and 270 nm. Method validation was performed according to ICH guidelines. The validated method is simple, rapid, mass compatible, economical, specific, accurate, linear, precise, rugged, sensitive, robust and stability indicating. This method can be employed for the simultaneous estimation of assay and related substance of remdesivir in bulk and injectable dosage forms at quality control laboratories of pharmaceutical industries.

A Novel Ultra Performance Liquid Chromatographic Method for the Estimation of Lercanidipine in Bulk and Tablet Dosage Form

Aim: In this present study an accurate reverse phase ultra-performance liquid chromatography (RP-UPLC) method has been developed, validated and applied to stability indicating studies to determine Lercanidipine HCL in bulk and marketed dosage form.&#x0D; Methods: Optimized chromatographic conditions were achieved by using Waters Acquity BEH C18 (2.1 x 50mm, 1.7m) UPLC column. Empower 2 is a software, dihydrogen Orthophosphate Buffer : Methanol (40 : 60) as eluent at flow rate 0.3 ml/min. PDA detection was performed at 254nm.&#x0D; Results: The developed method was validated and stability study was conducted as per ICH guidelines. The retention time was found at 0.503 min. The method shows linearity over a range of 1 μg/ml to 60 μg /ml with the obtained correlation coefficient is 0.999. The LOD and LOQ values were found 0.025 and 0.05 μg /ml. The acidic and peroxide stressed study shows more degradation of 6.23% and 3.03%.&#x0D; Conclusion: The present developed method was found stability indicating, reliable, validated method was applied for the routine analysis of lercanidipine in bulk drug and the pharmaceutical formulations.

A NEW NP-UPLC METHOD FOR THE SEPARATION AND SIMULTANEOUS QUANTIFICATION OF RAMUCIRUMAB AND ERLOTINIB

Objective: This investigation demonstrates a stability-indicating and reliable “normal phase ultra-performance liquid chromatography” method to simultaneously quantify Ramucirumab and Erlotinib in the pharmaceutical dosage form. Methods: Successful separation was accomplished using Chiralcel-OD-3 column (50 mm x 4.6 mm, 3 μm) with an isocratic type of elution using a mobile phase containing n-hexane+isopropyl alcohol+methanol (89:10:1), respectively with 1.0 ml/min flow rate. The wavelength sensor was attuned at 266 nm to quantify Ramucirumab and Erlotinib. Results: Erlotinib and Ramucirumab peaks were eluted with fine resolution at retention times 1.7807 min and 3.175 min, respectively. In the 10-150 μg/ml and 1-15 μg/ml concentration ranges for Erlotinib and Ramucirumab, the calibration graphs were linear, with regression coefficients of 0.99928 and 0.99976, respectively. The suggested ultra-performance liquid chromatography approach has been shown as sensitive, precise, robust, accurate, specific and stability indicating through the resolution of Erlotinib and Ramucirumab from its degradation-based compounds. Conclusion: The established ultra-performance liquid chromatography technique was effectively extended to the evaluation of Erlotinib and Ramucirumab in the pharmaceutical dosage form and the test results appeared satisfactory.

Simultaneous quantification of oxcarbazepine and its active metabolite in spiked human plasma using ultra performance liquid chromatography-MS/MS.

Aim: Clinical monitoring of oxcarbazepine (OXC) and its metabolite licarbazepine (MHD) in biological matrix requires a sensitive and validated analytical method. The aim of this study is to develop and validate an optimized ultra performance liquid chromatography-MS/MS based bioanalytical method for the simultaneous estimation of OXC and its metabolite MHD in human plasma, using deuterated internal standard method. Materials &methods: A reverse phase ultra performance liquid chromatography analysis and mass spectrometricdetection was performed using electrospray ionization in positive ion mode as interface, multiple reaction monitoringas mode of acquisition. Results &conclusion: The linearity range was 10-4011ng/mlfor OXC and 40-16061 ng/mlfor MHD. The kinetic parameters were calculated and compared for bioequivalence. This method fulfilled the validation guidelines, could be employed for determining bioavailability and in new formulation development studies.

New validated Reverse Phase Ultra Performance Liquid Chromatography method for drospirenone and estetrol in Active Pharmaceutical Ingredient and tablet form and its stress studies

The UPLC technique we have developed is completely unique and reliable and can quantitatively measure drospirenone and estetrol (E4) simultaneously. The chromatographic column of Luna C18 (100 × 2.6 mm, 1.6 µ) and isocratic elution, with a buffer (0.1% formic acid) and acetonitrile (30:70 v/v), using a flow of 1 ml/minutes at room temperature was used. The process was monitored by ultraviolet detection at 262 nm. A total of 3 minutes was dedicated to using a 3-minute timer to separate drospirenone and E4. Within the concentration range from 3 to 45 µg/ml of drospirenone and 14.2–213 µg/ml of E4, the analysis was completed in less than 5 minutes. System suitability parameters were studied and the outcomes were within acceptable limits when they were injected with the standard six times. To confirm the safety of the formulated product, a market-bought solution was assayed and it was found to be within specification. With all conditions and the acceptable range allowed, degradation studies were carried out on drospirenone and E4, all of which came back with a purity threshold that was higher than the purity angle. This particular technique was found to be consistent with the guidelines set forth by the International Council on Harmonization.